Premium
Response of chronic myelogenous leukemia patients to COAP—splenectomy. A southwest oncology group study
Author(s) -
Hester Jeane P.,
Waddell Caroline C.,
Coltman Charles A.,
Morrison Francis S.,
Stephens Ronald L.,
Balcerzak Stanley P.,
Baker Laurence H.,
Chen T. Timothy
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19841101)54:9<1977::aid-cncr2820540932>3.0.co;2-v
Subject(s) - medicine , splenectomy , chronic myelogenous leukemia , immunotherapy , randomization , leukemia , oncology , chemotherapy , surgery , clinical trial , cancer , spleen
Eighty‐seven patients from 18 institutions with a confirmed diagnosis of chronic myelogenous leukemia were registered on a Southwest Oncology Group protocol for multiagent induction and single‐agent maintenance chemotherapy, with randomization to an immunotherapy arm. Elective surgical splenectomy was performed for 42 patients at the completion of 3 months of induction therapy. Final analysis of the study revealed statistically significant survival advantages were correlated with age, splenectomy, the absence of hepatic leukemic infiltrate at the time of splenectomy, and race.